Yerevan State Medical University after Mkhitar Heratsi, Yerevan.
Tuberculosis Research and Prevention Center, Yerevan.
Monaldi Arch Chest Dis. 2021 Jan 14;91(1). doi: 10.4081/monaldi.2021.1648.
To evaluate factors associated with tuberculosis (TB) treatment outcomes in human Immunodeficiency Virus-Associated (HIV) TB patients in Armenia, we conducted a nation-wide cohort study using routine programmatic data of all HIV-associated TB patients receiving TB treatment with first- or second-line drugs from 2015 to 2019. Data were obtained from the TB and HIV electronic databases. We analysed occurrence of the combined unfavourable outcome (failure, lost to follow-up, death and not evaluated) and death separately, and factors associated with both outcomes using Cox regression. There were 320 HIV-associated TB patients who contributed a total of 351 episodes of TB treatment. An unfavourable TB treatment outcome was registered in 155 (44.2%) episodes, including 85 (24.2%) due to death, 38 (10.8%) lost to follow up, 13 (3.7%) failure and 19 (5.4%) not evaluated. Multivariable analysis showed that receipt of Antiretroviral Treatment (ART) [ART start before TB treatment: adjusted hazard ratio (aHR)=0.3, 95% confidence interval (CI): 0.2-0.5, aHR=, 95% CI:, 95% CI:, 95% CI:TB meningitis (aHR=4.4, 95% CI: 1.6-11.9) increased the risk. The risk of death was affected by the same factors as above in addition to the low BMI (aHR=2.5, 95% CI: 1.3-4.5) and drug resistance (aHR=2.3, 95% CI: 1.0-5.4). In the subsample of episodes receiving ART, history of interruption of ART during TB treatment increased the risk of unfavourable outcome (aHR=2.1 95% CI: 1.2-3.9), while ART start during TB treatment was associated with lower risk of both unfavourable outcome (within first 8 weeks: aHR: 0.5, 95% CI: 0.3-0.9; after 8 weeks: aHR: 0.4, 95% CI: 0.2-1.0) and death (within first 8 weeks: aHR: 0.2, 95% CI: 0.1-0.4; after 8 weeks: aHR: 0.1, 95% CI: 0.01-0.3). The rates of unfavourable TB treatment outcomes, and death in particular, among HIV-associated TB patients in Armenia are high. Our findings emphasize the protective effect of ART and the importance of proper management of cases complicated by drug resistance or meningitis.
为了评估与亚美尼亚人类免疫缺陷病毒相关性结核病(HIV-TB)患者的结核病(TB)治疗结局相关的因素,我们利用 2015 年至 2019 年所有接受一线或二线药物治疗的 HIV 相关性 TB 患者的常规规划数据,进行了一项全国性队列研究。数据来自 TB 和 HIV 电子数据库。我们分别分析了联合不良结局(失败、失访、死亡和未评估)和死亡的发生情况,并使用 Cox 回归分析了这两种结局的相关因素。共有 320 名 HIV 相关性 TB 患者,共贡献了 351 例 TB 治疗期。155 例(44.2%)出现不良 TB 治疗结局,其中 85 例(24.2%)因死亡,38 例(10.8%)失访,13 例(3.7%)治疗失败,19 例(5.4%)未评估。多变量分析表明,接受抗逆转录病毒治疗(ART)[在结核病治疗前开始 ART:调整后的危险比(aHR)=0.3,95%置信区间(CI):0.2-0.5,aHR=0.3,95%CI:0.1-0.6,aHR=0.1,95%CI:0.01-0.4]和结核病脑膜炎(aHR=4.4,95%CI:1.6-11.9)增加了风险。死亡风险还受到上述所有因素的影响,此外还受到低 BMI(aHR=2.5,95%CI:1.3-4.5)和耐药性(aHR=2.3,95%CI:1.0-5.4)的影响。在接受 ART 的治疗期病例亚组中,结核病治疗期间中断 ART 的历史增加了不良结局的风险(aHR=2.1,95%CI:1.2-3.9),而结核病治疗期间开始 ART 与不良结局(第 8 周内:aHR:0.5,95%CI:0.3-0.9;第 8 周后:aHR:0.4,95%CI:0.2-1.0)和死亡(第 8 周内:aHR:0.2,95%CI:0.1-0.4;第 8 周后:aHR:0.1,95%CI:0.01-0.3)的风险降低相关。亚美尼亚 HIV 相关性 TB 患者的不良 TB 治疗结局发生率,特别是死亡率很高。我们的研究结果强调了 ART 的保护作用,以及妥善管理耐药或脑膜炎合并症病例的重要性。